newsfilter
← Latest News
GlobeNewswire·

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

  • Preclinical data show deep, durable tumor regressions & significantly prolonged survival with ERNA-101 combined with PD-1 blockade in an ovarian cancer model.
  • Ernexa Therapeutics plans to submit an Investigational New Drug (IND) application for ERNA-101 in Q3 2026.
  • A first-in-human Phase 1 clinical trial for ERNA-101 targeting platinum-resistant ovarian cancer is scheduled to begin in Q4 2026.
  • ERNA-101 is an engineered synthetic induced-mesenchymal stem cell therapy designed to convert immunologically "cold" tumors into immune-responsive tumors by delivering cytokines to the tumor microenvironment.
  • The company expects to complete ERNA-101 clinical manufacturing process development in Q2 2026 & release the first product batch in Q3 2026.
  • Initial clinical data readouts for ERNA-101 are anticipated in the first half of 2027.
  • Advancement into Phase 2 trials for ERNA-101 with a potential co-development partner is planned for the second half of 2027.
  • A pre-IND meeting with the FDA for the autoimmune disease candidate ERNA-201 is expected in Q4 2026.
  • Ernexa completed a $10.5 million financing round & reduced general administrative expenses by approximately 61% in 2025.
  • The company successfully completed Pre-IND meetings with the FDA for ERNA-101 & finalized Proof of Principle studies for both ERNA-101 & ERNA-201.